Identification

Name
Meclizine
Accession Number
DB00737  (APRD00354)
Type
Small Molecule
Groups
Approved
Description

A histamine H1 antagonist used in the treatment of motion sickness, vertigo, and nausea during pregnancy and radiation sickness. [PubChem]

Structure
Thumb
Synonyms
  • Meclizine
  • Meclozine
  • Nevidoxine
Product Ingredients
IngredientUNIICASInChI Key
Meclizine HydrochlorideHDP7W44CIO31884-77-2BAAVORPTHSKWGJ-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AntivertTablet12.5 mg/1OralRoerig1997-04-11Not applicableUs
AntivertTablet25 mg/1OralRoerig1997-04-11Not applicableUs
AntivertTablet50 mg/1OralRoerig1997-04-11Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MeclizineTablet12.5 mg/1OralDirectrx2016-04-28Not applicableUs
Meclizine HydrochlorideTablet25 mg/1OralBlenheim Pharmacal, Inc.2009-12-16Not applicableUs
Meclizine HydrochlorideTablet25 mg/1OralRemedy Repack2014-11-122017-05-18Us
Meclizine HydrochlorideTablet25 mg/1OralEpic Pharma, LLC2012-04-30Not applicableUs
Meclizine HydrochlorideTablet50 mg/1OralAmneal Pharmaceuticals2010-02-12Not applicableUs
Meclizine HydrochlorideTablet25 mg/1OralRed Pharm Drug, Inc.2012-04-30Not applicableUs
Meclizine HydrochlorideTablet25 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1981-06-03Not applicableUs
Meclizine HydrochlorideTablet25 mg/1OralRemedy Repack2013-10-082016-11-03Us
Meclizine HydrochlorideTablet25 mg/1OralNorthwind Pharmaceuticals2015-02-26Not applicableUs
Meclizine HydrochlorideTablet12.5 mg/1OralCardinal Health2014-10-13Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BonamineTablet, multilayer, extended release25 mgOralMcneil Consumer Healthcare Division Of Johnson & Johnson IncNot applicableNot applicableCanada
Bonamine Tab 25mg ChewableTablet, chewable25 mgOralMcneil Consumer Healthcare Division Of Johnson & Johnson Inc1954-12-312011-08-04Canada
BonineTablet, chewable25 mg/1OralInsight Pharmaceuticals2009-06-08Not applicableUs
BonineTablet, chewable25 mg/1OralWell Spring Pharmaceutical Corporation2014-12-15Not applicableUs
BonineTablet, chewable25 mg/1OralWell Spring Pharmaceutical Corporation2017-04-18Not applicableUs
CVS Motion Sickness Fast MeltingTablet, orally disintegrating25 mg/1OralCVS Health2015-08-27Not applicableUs
Dramamine Less DrowsyTablet25 mg/1OralMedtech Laboratories, Inc.2011-09-01Not applicableUs
Jet-Avert Motion Sickness AidTablet25 mg/1OralBell International Laboratories2017-10-07Not applicableUs
Less Drowsy Formula Motion Sickness ReliefTablet25 mg/1OralSalado Sales, Inc.2002-06-24Not applicableUs
Less Drowsy Motion Sickness ReliefTablet25 mg/1OralRite Aid2002-06-242018-11-11Us
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Meclizine HCLTablet, chewable25 mg/1OralAdvance Pharmaceutical Inc.2013-07-01Not applicableUs
Meclizine HCLTablet, chewable25 mg/1OralRichmond Pharmaceuticals2015-05-01Not applicableUs
Meclizine HCL 12.5 mgTablet12.5 mg/1OralAdvance Pharmaceutical Inc.2013-07-01Not applicableUs
Rugby Travel Sickness Meclizine HCl, 25 mg Each (Antiemetic)Tablet, chewable25 mg/1OralNu Care Pharmaceuticals,inc.2014-08-19Not applicableUs
International/Other Brands
Chiclida / Meclicot / Navicalm / Postafen / Sea-Legs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Antivert TabMeclizine Hydrochloride (12.5 mg) + Niacin (50 mg)TabletOralPfizer1956-12-312000-01-24Canada
Categories
UNII
3L5TQ84570
CAS number
569-65-3
Weight
Average: 390.948
Monoisotopic: 390.186276581
Chemical Formula
C25H27ClN2
InChI Key
OCJYIGYOJCODJL-UHFFFAOYSA-N
InChI
InChI=1S/C25H27ClN2/c1-20-6-5-7-21(18-20)19-27-14-16-28(17-15-27)25(22-8-3-2-4-9-22)23-10-12-24(26)13-11-23/h2-13,18,25H,14-17,19H2,1H3
IUPAC Name
1-[(4-chlorophenyl)(phenyl)methyl]-4-[(3-methylphenyl)methyl]piperazine
SMILES
CC1=CC(CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=C(Cl)C=C2)=CC=C1

Pharmacology

Indication

For the prevention and treatment of nausea, vomiting, or dizziness associated with motion sickness.

Structured Indications
Pharmacodynamics

Meclizine, a piperazine-derivative H1-receptor antagonist similar to buclizine, cyclizine, and hydroxyzine, is used as an antivertigo/antiemetic agent. Meclizine is used in the management of nausea, vomiting, and dizziness associated with motion sickness and vertigo in diseases affecting the vestibular apparatus.

Mechanism of action

Along with its actions as an antagonist at H1-receptors, meclizine also possesses anticholinergic, central nervous system depressant, and local anesthetic effects. Meclizine depresses labyrinth excitability and vestibular stimulation and may affect the medullary chemoreceptor trigger zone.

TargetActionsOrganism
AHistamine H1 receptor
antagonist
Human
UNuclear receptor subfamily 1 group I member 3
inverse agonist
Human
Absorption

Well absorbed

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic

Route of elimination
Not Available
Half life

6 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include drowsiness and anticholinergic effects. LD50=mg/kg (orally in rat).

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Meclizine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Meclizine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Meclizine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Meclizine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Meclizine.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Meclizine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Meclizine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Meclizine.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Meclizine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Meclizine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Meclizine.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Meclizine.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Meclizine.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Meclizine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Meclizine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Meclizine.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Meclizine.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Meclizine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Meclizine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Meclizine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Meclizine.Experimental
AmphetamineAmphetamine may decrease the sedative activities of Meclizine.Approved, Illicit
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Meclizine.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Meclizine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Meclizine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Meclizine.Investigational, Vet Approved
AzelastineMeclizine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Meclizine.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Meclizine.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Meclizine.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Meclizine.Approved
BenzphetamineBenzphetamine may decrease the sedative activities of Meclizine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Meclizine.Approved
Benzylpenicilloyl PolylysineMeclizine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Meclizine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Meclizine is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Meclizine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Meclizine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Meclizine.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Meclizine.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Meclizine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Meclizine.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Meclizine.Approved, Investigational
BuprenorphineMeclizine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Meclizine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Meclizine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Meclizine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Meclizine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Meclizine.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Meclizine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Meclizine.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Meclizine.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Meclizine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Meclizine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Meclizine.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Meclizine.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Meclizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Meclizine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Meclizine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Meclizine.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Meclizine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Meclizine is combined with Chlorphenamine.Approved
ChlorphentermineChlorphentermine may decrease the sedative activities of Meclizine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Meclizine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Meclizine.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Meclizine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Meclizine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Meclizine is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Meclizine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Meclizine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Meclizine.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Meclizine.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Meclizine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Meclizine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Meclizine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Meclizine.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Meclizine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Meclizine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Meclizine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Meclizine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Meclizine.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Meclizine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Meclizine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Meclizine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Meclizine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Meclizine is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Meclizine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Meclizine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Meclizine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Meclizine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Meclizine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Meclizine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Meclizine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Meclizine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may decrease the sedative activities of Meclizine.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Meclizine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Meclizine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Meclizine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Meclizine.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Meclizine.Experimental
DiethylpropionDiethylpropion may decrease the sedative activities of Meclizine.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Meclizine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Meclizine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Meclizine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Meclizine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Meclizine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Meclizine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Meclizine.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Meclizine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Meclizine.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Meclizine is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Meclizine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Meclizine.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Meclizine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Meclizine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Meclizine.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Meclizine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Meclizine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Meclizine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Meclizine.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Meclizine.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Meclizine.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Meclizine.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Meclizine.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Meclizine is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Meclizine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Meclizine.Approved
EthanolMeclizine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Meclizine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Meclizine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Meclizine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Meclizine.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Meclizine.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Meclizine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Meclizine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Meclizine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Meclizine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Meclizine.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Meclizine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Meclizine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Meclizine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Meclizine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Meclizine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Meclizine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Meclizine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Meclizine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Meclizine is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Meclizine.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Meclizine.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Meclizine.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Meclizine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Meclizine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Meclizine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Meclizine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Meclizine.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Meclizine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Meclizine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Meclizine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Meclizine.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Meclizine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Meclizine is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Meclizine.Approved, Illicit, Investigational
GepefrineGepefrine may decrease the sedative activities of Meclizine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Meclizine.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Meclizine.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Meclizine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Meclizine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Meclizine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Meclizine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Meclizine.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Meclizine.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Meclizine.Approved, Investigational
HydrocodoneMeclizine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Meclizine.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Meclizine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Meclizine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Meclizine is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Meclizine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Meclizine is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Meclizine.Investigational
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Meclizine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Meclizine.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Meclizine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Meclizine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Meclizine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Meclizine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Meclizine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Meclizine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Meclizine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Meclizine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Meclizine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Meclizine is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Meclizine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Meclizine.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Meclizine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Meclizine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Meclizine.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Meclizine.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Meclizine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Meclizine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Meclizine.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Meclizine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Meclizine.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Meclizine.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Meclizine is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Meclizine.Experimental
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Meclizine.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Meclizine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Meclizine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Meclizine.Approved, Investigational
MephedroneMephedrone may decrease the sedative activities of Meclizine.Investigational
MephentermineMephentermine may decrease the sedative activities of Meclizine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Meclizine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Meclizine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Meclizine.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Meclizine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Meclizine.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Meclizine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Meclizine.Approved, Illicit
MethamphetamineMethamphetamine may decrease the sedative activities of Meclizine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Meclizine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Meclizine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Meclizine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Meclizine.Approved
MethotrimeprazineMeclizine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Meclizine.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may decrease the sedative activities of Meclizine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Meclizine is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Meclizine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Meclizine.Approved
MetyrosineMeclizine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Meclizine.Approved, Illicit
MidomafetamineMidomafetamine may decrease the sedative activities of Meclizine.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Meclizine is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Meclizine.Approved, Investigational
MirtazapineMeclizine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAMMDA may decrease the sedative activities of Meclizine.Experimental, Illicit
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Meclizine.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Meclizine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Meclizine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Meclizine.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Meclizine is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Meclizine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Meclizine.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Meclizine.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Meclizine.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Meclizine.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Meclizine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Meclizine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Meclizine.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Meclizine.Approved, Illicit
OrphenadrineMeclizine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Meclizine.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Meclizine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Meclizine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Meclizine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Meclizine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Meclizine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Meclizine.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Meclizine.Approved
ParaldehydeMeclizine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Meclizine is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Meclizine.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Meclizine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Meclizine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Meclizine.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Meclizine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Meclizine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Meclizine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Meclizine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Meclizine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Meclizine.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Meclizine.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Meclizine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Meclizine.Approved
PhenterminePhentermine may decrease the sedative activities of Meclizine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Meclizine.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Meclizine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Meclizine.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Meclizine is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Meclizine.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Meclizine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Meclizine is combined with Pomalidomide.Approved
PramipexoleMeclizine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Meclizine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Meclizine.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Meclizine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Meclizine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Meclizine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Meclizine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Meclizine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Meclizine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Meclizine is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Meclizine.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Meclizine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Meclizine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Meclizine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Meclizine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Meclizine.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Meclizine.Investigational
PseudoephedrinePseudoephedrine may decrease the sedative activities of Meclizine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Meclizine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Meclizine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Meclizine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Meclizine.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Meclizine is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Meclizine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Meclizine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Meclizine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Meclizine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Meclizine.Investigational
RitobegronRitobegron may decrease the sedative activities of Meclizine.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Meclizine.Vet Approved
RopiniroleMeclizine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Meclizine.Approved
RotigotineMeclizine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Meclizine.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Meclizine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Meclizine.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Meclizine.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Meclizine.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Meclizine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Meclizine.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Meclizine.Approved
StiripentolThe risk or severity of adverse effects can be increased when Meclizine is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Meclizine.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Meclizine.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Meclizine.Experimental
SuvorexantMeclizine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Meclizine.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Meclizine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Meclizine is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Meclizine.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Meclizine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Meclizine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Meclizine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Meclizine.Investigational
ThalidomideMeclizine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Meclizine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Meclizine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Meclizine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Meclizine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Meclizine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Meclizine.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Meclizine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Meclizine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Meclizine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Meclizine.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Meclizine.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Meclizine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Meclizine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Meclizine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Meclizine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Meclizine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Meclizine.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Meclizine.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Meclizine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Meclizine.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Meclizine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Meclizine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Meclizine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Meclizine.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Meclizine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Meclizine.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Meclizine is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Meclizine.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Meclizine.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Meclizine.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Meclizine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Meclizine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Meclizine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Meclizine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Meclizine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Meclizine.Vet Approved
ZolpidemMeclizine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Meclizine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Meclizine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Meclizine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Meclizine.Approved, Investigational
Food Interactions
  • Take with food to reduce irritation. Avoid alcohol.

References

Synthesis Reference

U.S. Patent 2,709,169.

General References
Not Available
External Links
Human Metabolome Database
HMDB14875
KEGG Compound
C07116
PubChem Compound
4034
PubChem Substance
46507782
ChemSpider
3894
BindingDB
81467
ChEBI
6709
ChEMBL
CHEMBL1623
Therapeutic Targets Database
DAP000795
PharmGKB
PA450338
IUPHAR
2757
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Meclizine
ATC Codes
R06AE55 — Meclozine, combinationsR06AE05 — Meclozine
AHFS Codes
  • 56:22.08 — Antihistamines

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHealthy Volunteers1
1RecruitingTreatmentHepatocellular,Carcinoma1
2CompletedTreatmentCessation, Smoking1
3RecruitingTreatmentVertigo, Peripheral1
4RecruitingOtherDrug Reaction1
Not AvailableCompletedTreatmentBenign Paroxysmal Positional Vertigo (BPPV)1
Not AvailableRecruitingPreventionProphylaxis against postoperative nausea and vomiting1

Pharmacoeconomics

Manufacturers
Packagers
Dosage forms
FormRouteStrength
TabletOral
Tablet, multilayer, extended releaseOral25 mg
Tablet, chewableOral25 mg
Tablet, orally disintegratingOral25 mg/1
TabletOral25 mg/1
TabletOral12.5 mg/1
TabletOral50 mg/1
Tablet, film coatedOral25 mg/1
Tablet, chewableOral25 mg/251
Tablet, chewableOral25 mg/1
Film, solubleOral25 mg/1
Prices
Unit descriptionCostUnit
Meclizine HCl 100 25 mg tablet Box89.97USD box
Antivert 50 mg tablet2.12USD tablet
Antivert 25 mg tablet1.23USD tablet
Meclizine hcl powder1.04USD g
Vertin-32 tablet0.9USD tablet
Antivert 12.5 mg tablet0.82USD tablet
Meclizine HCl 25 mg tablet0.67USD tablet
Meclizine 12.5 mg tablet0.62USD tablet
Sm motion sicknes 25 mg tablet0.5USD tablet
Meclizine HCl 12.5 mg tablet0.43USD tablet
Dramamine less drowsy tablet0.42USD tablet
Bonamine 25 mg Chewable Tablet0.33USD tablet
Dramamine 50 mg tablet0.28USD tablet
Meclizine 25 mg tablet0.07USD tablet
Medi-meclizine 25 mg tablet0.06USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)217-224U.S. Patent 2,709,169.
water solubility0.1gm/100mlNot Available
logP5.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00103 mg/mLALOGPS
logP5.59ALOGPS
logP6.39ChemAxon
logS-5.6ALOGPS
pKa (Strongest Basic)8.16ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area6.48 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity119.39 m3·mol-1ChemAxon
Polarizability44.87 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9318
Blood Brain Barrier+0.9656
Caco-2 permeable+0.6369
P-glycoprotein substrateSubstrate0.7422
P-glycoprotein inhibitor IInhibitor0.8149
P-glycoprotein inhibitor IINon-inhibitor0.8042
Renal organic cation transporterInhibitor0.7859
CYP450 2C9 substrateNon-substrate0.8416
CYP450 2D6 substrateNon-substrate0.5134
CYP450 3A4 substrateNon-substrate0.6059
CYP450 1A2 substrateInhibitor0.806
CYP450 2C9 inhibitorNon-inhibitor0.9698
CYP450 2D6 inhibitorInhibitor0.9521
CYP450 2C19 inhibitorInhibitor0.5209
CYP450 3A4 inhibitorNon-inhibitor0.8896
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7063
Ames testNon AMES toxic0.8536
CarcinogenicityNon-carcinogens0.9343
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.3803 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6113
hERG inhibition (predictor II)Inhibitor0.8104
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-052r-1920000000-da1d25573308648315fa
Mass Spectrum (Electron Ionization)MSsplash10-0ap0-1910000000-a39cf62803f22b3df281
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0090000000-66c42b235873c2a66976
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0090000000-02a85fbc5761853f587f
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0uxr-0590000000-4633d1c1f89a98d9a694
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0gb9-0940000000-38b1d47fb87eb43db9bd
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-0910000000-0787c462628db9403567
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-0900000000-9b3d5063cf1e4fd0ecda
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0udi-0390000000-10b11855a2539537e5af

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Phenylmethylamines / Benzylamines / Toluenes / N-alkylpiperazines / Chlorobenzenes / Aralkylamines / Aryl chlorides / Trialkylamines / Azacyclic compounds / Organopnictogen compounds
show 2 more
Substituents
Diphenylmethane / Benzylamine / Phenylmethylamine / Chlorobenzene / Halobenzene / Aralkylamine / N-alkylpiperazine / Toluene / Aryl chloride / Aryl halide
show 14 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
diarylmethane (CHEBI:6709)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Oishi R, Shishido S, Yamori M, Saeki K: Comparison of the effects of eleven histamine H1-receptor antagonists on monoamine turnover in the mouse brain. Naunyn Schmiedebergs Arch Pharmacol. 1994 Feb;349(2):140-4. [PubMed:7513381]
  2. Martins MA, Pasquale CP, e Silva PM, Pires AL, Ruffie C, Rihoux JP, Cordeiro RS, Vargaftig BB: Interference of cetirizine with the late eosinophil accumulation induced by either PAF or compound 48/80. Br J Pharmacol. 1992 Jan;105(1):176-80. [PubMed:1350745]
  3. Pasquale CP, e Silva PM, Lima MC, Diaz BL, Rihoux JP, Vargaftig BB, Cordeiro RS, Martins MA: Suppression by cetirizine of pleurisy triggered by antigen in actively sensitized rats. Eur J Pharmacol. 1992 Nov 13;223(1):9-14. [PubMed:1362160]
  4. Taniguchi K, Masuda Y, Takanaka K: Inhibitory effects of histamine H1 receptor blocking drugs on metabolic activations of neutrophils. J Pharmacobiodyn. 1991 Feb;14(2):87-93. [PubMed:1678430]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inverse agonist
General Function
Zinc ion binding
Specific Function
Binds and transactivates the retinoic acid response elements that control expression of the retinoic acid receptor beta 2 and alcohol dehydrogenase 3 genes. Transactivates both the phenobarbital re...
Gene Name
NR1I3
Uniprot ID
Q14994
Uniprot Name
Nuclear receptor subfamily 1 group I member 3
Molecular Weight
39942.145 Da
References
  1. Huang W, Zhang J, Wei P, Schrader WT, Moore DD: Meclizine is an agonist ligand for mouse constitutive androstane receptor (CAR) and an inverse agonist for human CAR. Mol Endocrinol. 2004 Oct;18(10):2402-8. Epub 2004 Jul 22. [PubMed:15272053]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34